Literature DB >> 23871717

Protective effect of nebivolol on reserpine-induced neurobehavioral and biochemical alterations in rats.

V S Nade1, N V Shendye, L A Kawale, N R Patil, M L Khatri.   

Abstract

Reserpine-induced orofacial dyskinesia is a model that shares some mechanists' aspects with tardive dyskinesia whose pathophysiology has been related to oxidative stress. The present study was aimed to explore neuroprotective effects of nebivolol, an antihypertensive agent, on reserpine-induced neurobehavioral and biochemical alterations in rats. Reserpine (1mg/kg, s.c.) was used to induce neurotoxicity. Administration of reserpine for 3 days every other day significantly increased the vacuous chewing movements (VCMs), tongue protrusions (TPs) and reduced the locomotor activity in rats. Pre-treatment with nebivolol (5 and 10mg/kg, p.o. for 5 days) showed dose dependant decrease in VCMs and TP induced by reserpine. Nebivolol also showed significant improvement in locomotor activity. Reserpine significantly increased lipid peroxidation and reduced the levels of defensive antioxidant enzymes like catalase (CAT), superoxide dismutase (SOD) and reduced glutathione (GSH) in rat brain. Nebivolol reversed these effects of reserpine on oxidative stress indices; indicating amelioration of oxidative stress in rat brains. The results of the present study indicated that nebivolol has a protective role against reserpine-induced orofacial dyskinesia. Thus, the use of nebivolol as a therapeutic agent for the treatment of tardive dyskinesia may be considered.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Nebivolol; Tardive dyskinesia; Vacuous chewing movements

Mesh:

Substances:

Year:  2013        PMID: 23871717     DOI: 10.1016/j.neuint.2013.07.002

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  7 in total

1.  L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats.

Authors:  Hung-Sheng Soung; Mao-Hsien Wang; Kuo-Chi Chang; Cheng-Neng Chen; Yi Chang; Chih-Chuan Yang; Hsiang-Chien Tseng
Journal:  Neurotox Res       Date:  2018-04-09       Impact factor: 3.911

2.  Nebivolol elicits a neuroprotective effect in the cuprizone model of multiple sclerosis in mice: emphasis on M1/M2 polarization and inhibition of NLRP3 inflammasome activation.

Authors:  Antoinette G Naeem; Reem N El-Naga; Haidy E Michel
Journal:  Inflammopharmacology       Date:  2022-08-10       Impact factor: 5.093

3.  The neuroprotective effect of Xylopia parviflora against aluminum chloride-induced neurotoxicity in rats.

Authors:  Ruth Edwige Kemadjou Dibacto; Bruno Dupon Akamba Ambamba; Fils Armand Ella; Christine Fernande Biyegue Nyangono; Jules Vidal Kamga Nanhah; Martin Fonkoua; Réné Samuel Minka; Judith Laure Ngondi
Journal:  Heliyon       Date:  2022-07-06

4.  Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Authors:  Fernanda F Peres; Raquel Levin; Mayra A Suiama; Mariana C Diana; Douglas A Gouvêa; Valéria Almeida; Camila M Santos; Lisandro Lungato; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; D'Almeida Vânia; Regina H Silva; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

5.  Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance.

Authors:  Yitav Glantz-Gashai; Tomer Meirson; Eli Reuveni; Abraham O Samson
Journal:  Drug Des Devel Ther       Date:  2017-06-19       Impact factor: 4.162

Review 6.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

7.  Neuroprotective potential of Beta vulgaris L. in Parkinson's disease.

Authors:  Vandana S Nade; Laxman A Kawale; Shankar S Zambre; Amit B Kapure
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.